Literature DB >> 6540170

Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.

R Riva, F Albani, G Ambrosetto, M Contin, P Cortelli, E Perucca, A Baruzzi.   

Abstract

The relationship between diurnal fluctuations in free (unbound) and total plasma carbamazepine levels and the appearance of intermittent side effects was investigated in nine epileptic patients receiving chronic therapy with carbamazepine, alone or in combination with phenobarbital. On a three-times-daily or four-times-daily dosing schedule, both total and free carbamazepine levels fluctuated considerably (on an average, 41 and 45%, respectively, around the mean). Side effects (particularly diplopia and nystagmus) were observed in five patients and showed an intermittent pattern in four. Side effects were never found at total carbamazepine levels less than 34 mumol/L but invariably appeared at levels greater than 38 mumol/L. At levels between 34 and 38 mumol/L adverse effects were inconsistently observed. The correlation between plasma carbamazepine levels and manifestations of toxicity was slightly stronger when free rather than total levels were considered. Side effects were always apparent at free levels greater than 7.2 mumol/L. These data underline the limitations of relying on a single drug level determination during the monitoring of carbamazepine therapy and emphasize the necessity of carefully adjusting the dosing schedule, to minimize the appearance of intermittent adverse effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540170     DOI: 10.1111/j.1528-1157.1984.tb03446.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  18 in total

1.  Simulated fluctuations in plasma drug concentrations for patients receiving oxcarbazepine or carbamazepine extended-release capsules.

Authors:  Alaa Ahmad; William R Garnett
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

2.  Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Authors:  Emilio Perucca
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

3.  Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.

Authors:  Laszlo Tothfalusi; Szilvia Speidl; Laszlo Endrenyi
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

4.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.

Authors:  P J McKee; J Blacklaw; E Butler; R A Gillham; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

7.  Impairment of psychomotor function at modest plasma concentrations of carbamazepine after administration of the liquid suspension to naive subjects.

Authors:  J D Wildin; B J Pleuvry; G E Mawer
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

Review 8.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 9.  Molecular clocks in pharmacology.

Authors:  Erik S Musiek; Garret A Fitzgerald
Journal:  Handb Exp Pharmacol       Date:  2013

10.  Carbamazepine extended-release capsules in bipolar disorder.

Authors:  Richard H Weisler
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.